Meristem Family Wealth’s GSK GSK Stock Holding History

Meristem Family Wealth’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-4,014	Closed	-$201K	–	208
2019 Q2	$201K	Buy	+4,014	New	+$201K	0.06%	166

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Meristem Family Wealth's GSK Position: Q3 2019 in Review

Meristem Family Wealth sold out of GSK (GSK) in Q3 2019, closing a stake of 4,014 shares — an estimated $201K sold.

Meristem Family Wealth first reported a position in GSK in Q2 2019 and held it in 1 quarter. The position peaked at $201K in Q2 2019. 805 funds tracked by Wall St. Rank hold GSK as of Q3 2019.

Meristem Family Wealth reported no remaining GSK position as of Q3 2019 after selling out during the quarter.
Meristem Family Wealth sold 4,014 GSK shares in Q3 2019, an estimated $201K.
Meristem Family Wealth first reported a position in GSK in Q2 2019 and held it in 1 quarter.
Meristem Family Wealth's GSK position peaked at $201K in Q2 2019.
805 funds tracked by Wall St. Rank held GSK as of Q3 2019.

Based on Meristem Family Wealth's 13F filing for Q3 2019, filed 8 Nov 2019.